Organization Profile

You just read:

First Patient Enrolled in CSL Behring PATH Trial to Evaluate Immune Globulin Subcutaneous (Human) 20% Liquid, Hizentra®, in the Treatment of CIDP

News provided by

CSL Behring

Mar 26, 2012, 10:51 ET